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Unique poly(L-lactic acid) (PLLA)-based scaffolds were constructed by embedding knitted 
PLLA yarns within a bioresorbable and differentially crosslinked three-dimensional (3D) 
oxidized collagen scaffold. The scaffolds were designed specifically for the repair of complex 
incisional abdominal wall hernias and the repair of defects within planar muscular tissues, such 
as the bladder. The chemical composition of the collagen matrix and the percentage of scaffold 
infiltration were compared for the different scaffold compositions. The results demonstrate that 
the incorporation of the collagen sponge within the PLLA scaffold facilitated bladder smooth 
muscle cell (bSMC) adhesion and proliferation. The highest dose of oxidized collagen (Oxicol) 
demonstrated better cell adhesion, resulting in the largest cell densities and most uniform 
distribution throughout the 3D collagen sponge. This formulation promoted the greatest α-
smooth muscle actin (αSMA) expression detected through immunohistochemical staining and 
western blotting. For abdominal wall repair applications, the proliferation and differentiation 
of C2C12 myoblasts and myotube formation were studied. Following 7 days of myogenic 
induction, the greatest expression of mRNA of the myogenic markers myogenin and MRF4 
was observed within the scaffolds with the highest dose of oxidized collagen, 1.5- and 3.85-
fold greater expressions, respectively, compared to PLLA with unmodified collagen. 
Furthermore, in vitro myotube formation and MyMC expression were enhanced in the Oxicol 
scaffolds. We conclude that the Oxicol scaffold formulation with a high-dose oxidized collagen 
ratio provides enhanced myogenesis and αSMA, and the biological induction cues necessary 
to achieve better tissue integration, than standard PLLA scaffolds in the treatment of complex 
abdominal wall hernias. 




Keywords: large complex abdominal wall defect; incisional hernia;  tissue engineering; 
skeletal muscle; smooth muscle; PLLA; collagen; biodegradable polymers 
  
1. Introduction 
Of all patients who undergo any form of abdominal surgery, 11–20% suffer an incisional hernia 
(Mudge and Hughes, 1985; Santora and Roslyn, 1993; Sugerman et al., 1996), where a 
weakness in the soft tissue results in postsurgical mechanical failure of the abdominal wall’s 
integrity. This rises to approximately 20% of all bariatric surgeries (Hodgson et al., 2000; 
Luijendijk et al., 2000; Cassar and Munro, 2002; Hoer et al., 2002; Sorensen et al., 2005; 
Kingsnorth, 2006; Millennium Research Group, 2009, 2010). Currently, 150 000 failures occur 
in the four largest markets in Europe (Millennium Research Group, 2009) and 350,000 cases 
are treated in the USA every year (Millennium Research Group, 2010). In each market there is 
a current growth rate of incidence of herniation of 3%/year, with an estimated>1 million 
patients/year, globally, requiring treatment. In obese patients, those with chronic renal disease, 
diabetics and those undergoing immunosuppressive or radiation therapy, acute wound-healing 
failure is most often the direct cause. The aetiology of the failure strongly suggests reduced 
blood flow and immunological factors, with high levels of bacterial contamination and necrosis 
at the site of herniation commonly observed (Leber et al., 1998). No ideal surgical management 
procedure as yet exists, because repair surgery results in subsequent failure of the closure in a 
large proportion of incisional hernias, up to 54% in suture repairs and 36% in mesh repairs 
(Hodgson et al., 2000; Burger et al., 2004) requiring re-operation. Current technologies and 
changes to surgical practice have not improved the rate of incisional herniation over the past 
decade (Bellon, 2007) and only marginally over the past century (Carlson, 1997). The 
estimated annual cost of incisional hernia repair was $2.5 billion in the USA alone in 2001 
(Arrow, 2001). Current procedures to repair ventral hernias can result in adhesions which may 
be extremely painful, often requiring further re-operation. Additional to these figures is the cost 
due to loss of economic activity and huge loss of quality of life in the affected patients. 
Ventral hernias are termed ‘complex’ when: (a) they involve a surgical field that has 
been compromised due to tissue bacterial contamination; (b) the presence of gastrointestinal or 
biliary contents, due to a fistula or ostomy, loss of abdominal domain (presence of a large 
hernia sac) or dimensions that are >10 cm in any direction; (c) or are a re-operation of a 
contaminated mesh or re-opened ventral hernia. The repair of large, complex ventral hernias, 
which occur more commonly in obese patients, suffer exaggerated rates of bacterial 
contamination and necrosis. As the tissue immediately adjacent to the wound site is often 
exposed to enteric contents, it is very common for the closure of these hernias to fail (or fail 
again), leading to chronic repeat operations and, for obvious reasons, complete loss of quality 
of life and economic output for the patient. Complex hernias often require extensive 
debridement of contaminated tissue around the hernia. Synthetic meshes are contra-indicated 
in the repair of these hernias (Blatnik et al., 2008), due to the high rate of chronic 
contaminations that they subsequently harbour, due to low vascularization and tissue necrosis. 
However, autologous tissue is not often easily, surgically available in these patients. Acellular 
matrix grafts, such as allogeneic dermis grafts that have been decellularized and defatted from 
biological tissues, have demonstrated successful abdominal wall reconstruction and some 
resistance to bacterial contamination (Park et al., 2006), but they are generally only slowly 
remodelled as a neotissue or are degraded too quickly (Valentin et al., 2006). 
There is an urgent need, therefore, for a biosynthetic alternative whose degradation 
properties can be tuned and which not only supports or enhances the growth and integration of 
abdominal wall cells and tissue, but which will allow or induce adequate levels of angiogenesis 
and vascularization. This will aid in prevention of necrosis and inhibition of chronic implant 
contamination.  
In general, synthetic polymers have good mechanical strength, but they are relatively 
hydrophobic and hinder cell adhesion. Conversely, naturally derived polymers, such as 
collagen, contain a variety of cell adhesion domains whilst being hydrophilic. However, 
scaffolds constructed entirely from purified collagen fibres have generally demonstrated poor 
mechanical strength. 
In this study, a novel design approach was taken by combining the advantageous 
biological properties of collagen with the strength of a synthetic PLLA scaffold, using a new 
chemical modification of collagen to modulate its degradation profile. A review of the literature 
has revealed that, until now, there have been no reports of collagen–PLLA composite materials 
for the repair of large complex abdominal wall defects. These considerations formed the 
motivation for the research described here.  
Engineering skeletal muscle tissue for the repair of an abdominal wall defect requires 
the proliferation and differentiation of mononucleated muscle precursor cells (myoblasts) and 
their fusion into multinucleated myotubes, followed by the alignment of the myotubes into 
fibres (Wigmore and Dunglison, 1998). In this study, we used C2C12 myoblasts because they 
have been shown to faithfully mimic skeletal muscle differentiation in vitro, as shown by their 
induction to terminally differentiated myotubes following withdrawal of serum from the culture 
medium (Yaffe and Saxel, 1977; Pownall et al., 2002; Parker et al., 2003). Myogenic 
regulatory factors (MRFs) are skeletal muscle-specific transcription factors that are expressed 
during myogenic differentiation, the most important of which are MyoD, myogenin, Myf-5 and 
MRF-4. Myf5 and MyoD are required for myoblast lineage specificity; myogenin is critical for 
the function of MRF-4 and differentiation; whilst myosin heavy chain II (MyHC) is expressed 
in fully differentiated fibres. In this study, we comprehensively studied the expression of 
myogenic regulator genes and proteins and determined whether the PLLA–collagen three-
dimensional (3D) scaffolds were able to support myogenic differentiation and myotube 
formation. 
αSMA is an important marker of functional bladder smooth muscle cells (bSMCs). We 
also investigated in the present study whether the PLLA–collagen scaffolds were able to sustain 
bSMC adherence, proliferation and continued expression of αSMA over an extended period, 
to determine whether the design was also appropriate for smooth muscle-containing 
regenerated tissue, such as tissue-engineered bladder. We also researched the best combination 
of PLLA–collagen 3D scaffolds for bladder applications by monitoring the expression of the 
SMC functional protein αSMA within the scaffold.  
 
2. Materials and Methods 
2.1. Preparation of collagen 
Porcine collagen type I was extracted from porcine dermis by solubilization at acidic pH or by 
digestion with pepsin, and then purified by saline precipitation (Tinois et al., 1991; Afanasiev 
et al., 1999). Dry collagen fibres were obtained by precipitation of an acid solution of collagen 
by adding NaCl, then subsequent washing and drying of the precipitate, using increasing 
concentrations of acetone in the range 80–100%. 
  
2.2. Glutaraldehyde (GTA)-crosslinking of collagen  
Porcine collagen was crosslinked using glutaraldehyde (GTA) to inhibit complete. Collagen 
solution of 1% w/v concentration was neutralized using sodium phosphate at a final 
concentration of 20 mM, the resultant pH adjusted to be in the range 6.5–7.5. GTA (25% w/v; 
Fluka AG, Buchs, Switzerland) was added to the suspension at a final concentration of 0.5–
0.8% w/v. Following 2 h incubation at ambient temperature, the collagen fibres were recovered 
by filtration of the suspension through a nylon mesh. The fibres were then treated with sodium 
borohydride for at least 2 h until the yellow colouration of the fibres had completely 
disappeared. The white fibres thus obtained were washed and neutralized at pH 6.5–7.5, and 
dried by removal of the water using acetone. The fibres were stored at -20°C following acetone 
removal by evaporation. 
 2.3. Chemical modification of collagen (fabrication of Oxicol) 
The oxidation of porcine collagen (Oxicol formation) allows for its short-term remodelling 
when implanted in a host. Collagen was prepared by dissolving in 0.01 N HCl at a concentration 
of 30 g/l, then mixing with periodic acid to a final concentration of 8 mM. Oxidation was 
performed at an ambient temperature close to 22°C for 3 h in the dark. An equal volume of a 
solution of sodium chloride was added to obtain a final concentration of 41 g/l NaCl. The 
precipitate was collected after 30 min by decantating through a fabric filter (porosity of 100 
μm), then washing four times with a 41 g/l solution of NaCl in 0.01 N HCl to form an acid 
saline precipitate. This washing process eliminated all traces of periodic acid and iodine 
derivatives formed during oxidation of the collagen. The collagen precipitate was washed 
several times in an aqueous solution of 80% acetone to eliminate the remaining salts. A final 
wash in 100% acetone was used to prepare a very dense acetone precipitate of acid-oxidized, 
non-reticulated collagen, with no trace of undesirable chemical products (Tinois et al., 1991). 
The precipitate was finally suspended in demineralized water at a concentration of 1% w/v and 
stored at 4°C. 
 
2.4. Preparation of poly-(L-lactic acid) (PLLA) scaffold 
A 3D PLLA–collagen scaffold was manufactured that had a unique structure, having collagen 
sponges formed within the pores of a mechanically strong knitted mesh of PLLA, as shown in 
Figure 1. Briefly, a 3D knit was prepared on a double-needlebar Raschel knitting machine, with 
six guide bars. Each of the faces of the knit, i.e. the first face and the second face, was prepared 
with two guide bars. The first face was prepared with bars B1 and B2, and the second, opposite, 
face was prepared with bars B5 and B6, each bar being threaded one full, one empty. 
Bars B1 and B2, and B5 and B6, which produce the first and second faces of the knit, 
were threaded with PLLA 83.3 dtex multifilament yarn (decitex count 83.3 g/10,000 m yarn). 
The spacer was prepared using bars B3 and B4, threaded one full, one empty. 
Bar B3 was threaded with PLLA 220 dtex monofilament yarn, so as to give thickness 
and resilience to the 3D knit. Bar B4 was threaded with PLLA 83.3 dtex multifilament yarn so 
as to give greater opacity between the faces. 
The filament diameter of the multifilament yarns and the monofilament yarns were 
approximately 18 and 220 μm, respectively (Figure 1) and produced an isoelastic mesh of the 
following characteristics: weight/surface area of 116.5 g/m2; macro pore size approximately 
2×2 mm; thickness 3.1 mm; and 3D porosity 97%. 
 2.5. Preparation of PLLA mesh–collagen composite scaffolds 
Porcine collagen that was GTA-crosslinked or oxidized (representing both long and short-term 
degradation profiles, respectively; modification proportions of 80:20 and 50:50 were studied) 
were mixed at a ratio of either 80:20 or 50:50, respectively, and poured over the 3D PLLA 
mesh to completely cover it (note: the topside of the scaffold is referred to as the ’sponge side’, 
whilst the lower side will be referred to as the ’mesh side’, in the remainder of the paper). The 
scaffold was lyophilized for 24 h and then sterilized by γ-irradiation at a minimum dose of 25 
kGy. The precise scaffold architecture was defined by selecting the collagen mixture ratio, 
crosslinking density and yarn filament structure that achieved the best mechanical properties 
and in vivo biological performance (Pu et al., 2010). The three scaffolds compared in this study 
were: PLLA coated with unmodified collagen that did not form a secondary 3D structure 
(scaffold A); PLLA with low-dose Oxicol and high-dose GTA (scaffold B); and PLLA coated 
with high-dose Oxicol and low-dose GTA (scaffold C). These are detailed in Table 1. 
 
2.6. Scanning electron microscopy (SEM) 
The structures of the PLLA–collagen scaffolds with and without cells were determined using 
a field emission scanning electron microscope (FE-SEM; LEO 1550, Cambridge, UK). Briefly, 
small pieces of the scaffold were coated with chromium (approximately 50 nm thick) under 
125 mA. The coated samples were placed in the vacuum chamber of the FE-SEM and viewed 
at a voltage of 5 kV. 
 
2.7. Isolation and culture of cells 
2.7.1. Porcine bSMCs 
Fresh porcine bladder specimens were collected in sterile phosphate-buffered saline (PBS). 
The bladder was cut in half and the urothelial layer peeled off from the luminal surface of the 
bladder under sterile conditions. The bladder muscle tissue was cut into small pieces, re-
immersed in collagenase solution (2 mg/ml collagenase type IV) and then incubated at 37°C 
for 40 min on a roller-mixer. The supernatant was aspirated and complete medium added 
[Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS) and 
penicillin–streptomycin]. The bladder pieces were minced evenly onto 150 mm tissue culture 
dishes in a few drops of complete medium and incubated at 37°C, 5% CO2, for 30 min to 
promote tissue adherence. Complete medium was then added and the dishes returned to the 
incubator. The medium was replaced every 2–3 days until 80% confluence had been achieved, 
at which point the cells were split at a ratio of 1:3. Cells at passages 4–6 were used for these 
studies. Morphological examination and immunohistochemical staining for αSMA were used 
to confirm the cell identity and homogeneity of the cultures. 
 
2.7.2. C2C12 myoblasts 
Undifferentiated myoblasts from a cell line originating from mouse skeletal muscle (ATCC) 
were grown in DMEM supplemented with 10% FCS and antibiotics [growth medium (GM)] 
at 37°C and 5% CO2. The differentiation medium (DM) contained 2% horse serum instead of 
10% FCS. The cells were passaged by trypsinization (0.5% trypsin in 0.5 mM EDTA; Gibco, 
UK) from the culture plate at 70% confluence. To demonstrate active C2C12 differentiation, 
cells were seeded at a density of 5 × 104/cm2 and cultured to 70% confluence in DMEM and 
10% FCS, followed by DM for 5 days.         
 
2.8. Scaffolds and cell seeding 
The 3D composite sponges, 2–3 mm thick, were fabricated as 15 mm diameter discs. The 
different formulations of crosslinking and oxidation of the porcine collagen are listed in Table 
1. To evaluate cell adhesion, proliferation, phenotype and protein expression on the scaffold, 
bSMCs were seeded at a density of 105/scaffold in a 24-well plate and cell viability, 
proliferation, immunohistochemical staining and western blotting were evaluated at 1, 7 and 
21 days. 
To assess whether the scaffolds supported myogenic differentiation, myoblasts were 
seeded at a density of 5 × 105/scaffold and incubated in GM overnight, then in DM for 7 days. 
Cells were analysed for the expression of myogenic genes and protein expression by 
quantitative RT–PCR and immunohistochemical staining, respectively. 
 
2.9. Cell viability and cell proliferation assay 
A two-colour fluorescence cell viability assay was used, based on the ability of calcein AM to 
be retained within live cells, inducing an intense uniform green fluorescence and ethidium 
homodimer (EthD-1) to bind the nuclei of damaged cells, thus producing a bright red 
fluorescence in dead cells. Cell-loaded scaffolds were washed with PBS for 5 min and then 
submerged in a live/dead staining solution containing 2 μM calcein AM and 4 μM EthD-1. The 
samples were incubated for 30 min at 37°C, 5% CO2 in the dark. Fluorescence images were 
acquired immediately using a laser scanning confocal microscope (Carl Zeiss 510). 
To analyse the proliferation of porcine bSMCs following their seeding on the different 
scaffolds, a CyQUANT cell proliferation assay kit was used (Molecular Probes, Invitrogen, 
UK). The basis for the CyQUANT assay is the use of a proprietary green fluorescent dye 
(CyQUANT GR dye) that exhibits strong enhancement of fluorescence when bound to cellular 
nucleic acids. Cells were lysed with a buffer containing CyQUANT GR dye. Fluorescence was 
measured using an FLX800 fluorimeter (Bio-Tek Instruments), with excitation at 485 nm and 
emission at 530 nm. Sample fluorescence values were converted into cell numbers from a 
bSMC reference standard curve. The results are presented as a mean of four experiments ± 
standard error of the mean (SEM). 
 
2.10. Quantitative RT-PCR 
To determine myogenic gene expression by quantitative RT–PCR, total RNA was isolated at 
various time points, using an RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
protocol. Total RNA (1 μg) was reverse-transcribed to cDNA, using SuperScriptTM III reverse 
transcriptase and oligo(dT) (Invitrogen, UK) in a total reaction volume of 20 μl. The 
amplification was performed with a LightCycler 480 SYBR Green I Master (Roche 
Diagnostics). Amplification included a denaturation step at 95°C for 5 min, followed by 45 
cycles at 95°C for 10 s, 55°C for 15 s and 72°C for 20 s. To verify amplification specificity, 
melting curves of the PCR products of each primer set were analysed. Each experiment was 
prepared in triplicate and data represented as mean ± standard deviation (SD) of four 
independent experiments. The sequences of the primers used are shown in Table 2. Relative 
expression level was computed for the RT–PCR data by the ΔΔCT method, using GAPDH as 
the reference gene (Livak and Schmittgen, 2001; Pfaffl, 2002). All measurements of CT values 
for each determination of the reference and experimental gene expression were performed in 
triplicate.  
 
2.11. Immunohistochemical staining and western blotting 
Cell-laden scaffolds or cell cultures on tissue culture plastic were fixed in 4% formaldehyde, 
blocked with normal horse serum and incubated with the appropriate antibody. For the study 
of bSMCs, SMC-specific contractile filament protein αSMA (1A4, 1:200; Sigma, UK) and 
smooth muscle myosin heavy chain (SM-MHC, G-4, 1:400; Santa Cruz Biotechnology) 
monoclonal antibodies were used. To determine myogenic differentiation, monoclonal 
antimyosin heavy chain II (MyHC, 1:400; Abcam, UK) was utilized. Immunohistochemical 
staining was achieved using a secondary biotinylated antibody (1:200), followed by a 
Vectastain ABC-AP kit (AK5000, Vector Laboratories, UK) and the addition of the appropriate 
AP substrate (SP5000), to which levamisole solution had been added. Colour was developed 
for 20 min. Cell nuclei were stained by 4′-6-diamidino-2-phenylindole (DAPI; Vector 
Laboratories). Negative controls were for an anti-rabbit IgG, or deletion of the primary 
antibody in experiments where a secondary antibody was used. Images were acquired using 
laser scanning confocal microscopy (LSM 510, Zeiss, Germany).  
Quantitative analysis of αSMA protein was performed using western blotting. bSMCs 
were cultured on PLLA–collagen scaffolds for up to 21 days and then washed twice with PBS 
and lysed in 400 μl Tris lysis buffer (0.01 M Tris, pH 7.4, and 1% sodium dodecyl sulphate). 
Following centrifugation, the protein concentration was determined by Bradford assay (Sigma, 
UK) with bovine serum albumin (BSA) as the standard. To detect protein expression, 30 μg 
total protein was separated by 10% SDS–PAGE. The protein fraction was transferred to a 
nitrocellulose membrane (Sigma), blocked with 3% BSA in 1× Tris-buffered saline with 
Tween (TBST; 10 mM Tris, 150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature and 
then probed overnight with anti-αSMA monoclonal primary antibody (1:500; Abcam). HRP-
conjugated secondary antibody (Santa Cruz Biotechnology) was incubated with the membranes 
for 1 h. Equal protein loading for these samples was confirmed by examining GAPDH 
expression. The chemiluminescent detection system ECL/ECL (Geneflow) enabled 
visualization following exposure to X-ray film. Autoradiographs were quantified by 
densitometry, using the Synoptics Group gene tools BioImaging system software (Syngene, 
Cambridge, UK) according to the manufacturer’s instructions. 
 
2.12. Statistical analysis 
Statistical analysis was performed using SPSS v. 17 (Statistical Analysis Software, NC, USA). 
Data of gene expression and cell numbers were presented as arithmetic mean ± SD. For 
descriptive data, statistical evaluation was achieved by analysis of variance (ANOVA) with 
Tukey and Waller–Duncan’s multiple comparison tests being applied to detect differences 
between groups. Four repeats/material/time period were assessed. In all statistical evaluations, 
p<0.05 was considered statistically significant. 
 
3. Results 
3.1. Characterisation of PLLA-collagen scaffolds 
The morphology of the PLLA–collagen scaffolds, as observed by SEM, are displayed in Figure 
1. PLLA mesh coated with collagen (scaffold A, Figure 1a–c) is a bundle-knitted structure 
having a wide texture (Figure 1a) with a fibre diameter of approximately 20 μm (Figure 1b) 
and comprising various sheet structures (Figure 1c). PLLA–collagen composite (lower-dose 
Oxicol, scaffold B; Figure 1d–f) has collagen filaments masking the bundle-knitted structures 
(Figure 1d). In this formulation, collagen is more abundant on the top surface than on the 
bottom (Figure 1f). In addition, the scaffold surface was largely covered by the collagen coating 
(Figure 1e). A similar situation was observed in scaffold C (Figure 1g–i, higher-dose Oxicol). 
Collagen sponges with interconnected micropores formed in the interstices of the synthetic 
polymer mesh. The polymer mesh was embedded in the collagen sponge, such that the polymer 
fibre bundles and the collagen sponges were alternately chained. Observation by SEM 
demonstrated that the pores were distributed evenly in the scaffolds that had collagen sponges 
(scaffolds B and C). This was confirmed by micro-computed tomography (μCT) analysis. The 
degree of porosity was determined to be approximately 81% and the mean pore size 110 μm. 
In addition, the 3D scaffold was constructed with bioresorbable material which has an expected 
in vivo degradation time in the range ca. 3 months–2 years, as previously reported for 
crosslinked collagens (Paul and Bailey, 2003) and for Oxicol scaffolds (Pu et al., 2010). The 
mesh has isoelastic mechanical properties in the range suitable for tissue-engineering 
applications. 
 
3.2. Characterisation of primary-derived bSMCs 
bSMCs were successfully established from porcine bladders. Following isolation, the bSMCs 
adhered and grew out from the bladder tissue during the first 2 days and multiplied rapidly to 
form uniform spindle-shaped cells, which were identified by phase-contrast microscopy 
(Figure 2a). Isolated primary cells can be identified by their affinity to antibodies against 
αSMA; > 95% of the cultured bSMCs stained positively for αSMA. bSMCs expressed 
prominent αSMA-labelled thick filaments in the cytoplasm (Figure 2b). Confluent monolayers 
of bSMCs exhibited characteristic ‘hill and valley’ morphology in culture and expressed SM-
MHC (Figure 2c). 
 
3.3. Viability, proliferation and distribution of bSMCs on scaffolds 
bSMCs were viable after seeding on 3D scaffolds during the experimental period. After 1 day 
in culture (Figure 3a–c), cells adhered to the scaffolds, but many were not well spread. Over 
time, the cell numbers increased and were evenly distributed throughout the scaffolds. Up to 
14 days (Figure 3d–f), cells grew rapidly on the scaffolds that had collagen sponge (scaffolds 
B and C) compared to scaffold A, which did not, and which had a greater number of dead cells. 
Moreover, the cells were distributed to the bottom of scaffold C compared to scaffold B. 
As observed using SEM, scaffold C was covered by a dense cell layer on its surface 
after 7 days. In contrast, the surface of scaffolds A and B exhibited less cell coverage of the 
top surface and only a few cells observed on the under-surface. By 21 days, the bSMCs had 
formed a confluent layer covering both surfaces on scaffold C (Figure 3i, l), suggesting that 
cells were able to migrate throughout the scaffold and fill the entire construct. In contrast, only 
60% of the surface of scaffold B was covered by cells (Figure 3h, k). Scaffold A only had a 
few cells on its fibres (Figure 3g, j), suggesting that the structure had severe limitations in 
supporting cell growth. 
At day 1, the number of cells, as measured by the CyQuant assay, that were adhered to 
both scaffolds B and C (sponge-filled) were significantly greater than on scaffold A (Figure 
3n). This was observed also on days 7 and 21. After 7 days, scaffold C had the highest cell 
numbers, although the numbers of cells had also increased slightly on scaffold A. At day 21, 
cell proliferation rates were significantly higher (p<0.001) in scaffold C, whereas cell numbers 
had plateaued by 7 days in scaffold B. 
 
3.4. Expression of α-SMA on bSMCs  
Expression of αSMA, a marker of SMCs, is shown in low (Figure 4a, c, e) and high (Figure 
4b, d, f) magnifications. The cells cultured on scaffold C showed intense staining for αSMA 
(Figure 4f, g), demonstrating that this scaffold not only supports cell proliferation but also 
sustains the smooth muscle cell phenotype, which has muscle function. To further confirm 
these results, αSMA protein production in the scaffolds was investigated by western blotting 
at 21 day (Figure 4g). A two-fold increase in αSMA protein expression was demonstrated on 
scaffold C compared to scaffold A. This result further confirms that PLLA–collagen scaffold 
with the higher dose of Oxicol is best at supporting cell growth whilst maintaining the specific 
SMC phenotype. 
  
3.5. Characterisation of myoblast differentiation 
Undifferentiated C2C12 myoblasts (Figure 5a) cultured in differentiation medium for 5 days 
demonstrated the presence of multinucleated, elongated myotubes under phase-contrast light 
microscopy (Figure 5b). During this culture period, expression of the MRF genes myogenin 
and MFR4 was significantly increased, by a factor of 26 and 141, respectively, compared to 
undifferentiated cells (Figure 5c). Expression of the proliferation marker MyoD did not change. 
 
3.6. Myogenic differentiation and myotube formation 
C2C12 myoblasts seeded on the scaffolds in differentiation media and cultured for 7 days were 
analysed by quantitative RT–PCR (Figure 6a). The expression of MyoD was at its highest 
intensity at day 1 compared to day 7 for all scaffolds. After 1 day in myogenic differentiation 
culture, MyoD expression was 2.65- and 2.80-fold greater in scaffolds B and C, respectively, 
than in scaffold A, which was 1.59-fold higher than the baseline of the uncommitted cells 
(Figure 6a). Expression of the late myogenic markers myogenin and MFR4 increased 
significantly at day 7 compared to day 1. Following 7 days of myogenic induction, upregulation 
of myogenin had increased 26-fold on scaffold C, whilst MFR4 was expressed 167-fold higher. 
These figures are 1.5 and 3.85 times greater than those observed for scaffold A. Statistically, 
expression of myogenin and MFR4 mRNA was significantly different within the group 
(p<0.001; Figure 6a), indicating that scaffold C supportedmyogenic differentiation into the 
later stages better than the other scaffolds. 
To further confirm the results of the quantitative RT–PCR analysis, the capability of 
the C2C12 cells to fuse and differentiate into multinucleated myotubes on the 3D scaffolds was 
further investigated by means of immunofluorescent staining for MyHC. MyHC is expressed 
in terminally differentiated skeletal muscle cells and is a late marker of myogenic commitment. 
The expression of MyHC was observed mostly in multinucleated myotubes. Cells were seen 
to adhere and proliferate throughout the scaffold. Figure 6b shows evidence of cell nuclei lining 
up along the direction of the scaffold fibres, suggesting the presence of multinucleated 
myotubes running parallel to the scaffold fibrous structure. This supposition was confirmed by 
observation of myosin expression (MyHC; Figure 6b, stained red, cell nuclei in blue) when 
cultured in DM for 7 days. A high degree of orientation of myotubes was observed in cells on 
scaffold C (Figure 6b). Conversely, few myotubes were expressed in scaffolds A or B. 
 
4. Discussion 
The design and selection of a biomaterial for engineering muscular tissues requires appropriate 
regulation of cell behaviour (e.g. adhesion, proliferation, migration and differentiation) to 
promote the development of functional new tissue in the absence of adverse host reactions (e.g. 
inflammation). This study demonstrated that biodegradable collagen–PLLA composite 
scaffolds combined with a novel collagen formulation fully supports the maturation and 
differentiation of SMCs and myoblasts, strongly suggesting that these scaffolds, by virtue of 
their specific formulation and design, are good candidates for the reconstruction of muscular 
tissue defects, in particular the abdominal wall and bladder, through enhancement of the 
regeneration of both skeletal and smooth muscle components. PLLA–collagen scaffold 
comprising higher-dose Oxicol sponge provided the best results, not just in its ability to sustain 
myogenic differentiation and myotube formation, but also in supporting bSMC cell adhesion 
and proliferation and also the secretion of SMC functional proteins, which were strongly 
expressed, as determined by immunofluorescence and western blotting. 
The repair of large, complex abdominal wall defects is often compromised by factors 
related to the health of the patient, including diabetes, which is implicated in exacerbated 
wound bacterial contamination and obesity, resulting in impaired wound healing. Diabetic 
patients suffer impaired endothelial progenitor cell (EPC) recruitment from the bone marrow, 
due to reduced SDF-1α expression in the myofibroblastic cell population (Brem and Tomic-
Canic, 2007). The reduced numbers of EPCs result in reduced vasculogenesis and therefore 
reduced peripheral blood flow, resulting in a diminished local wound-healing response. This 
reduced blood flow further decreases the ability of diabetic patients to fight bacterial 
contamination, meaning that wounds are more likely to become contaminated, further 
hindering normal wound healing. The presence of wound contamination is particularly 
problematic, as subsequent necrosis dramatically increases wound closure-failure rates. Of 
course, any condition that increases intra-abdominal pressure, including obesity and chronic 
pulmonary disease, is additionally liable to result in increased defect repair-failure rate. 
Furthermore, patients using corticosteroids also have impaired abdominal wall physiology 
(Ehrich and Hunt, 1968; Wicke et al., 2000). 
The abdominal wall comprises six layers: skin, subcutaneous fascia, musculature, 
transversalis fascia, preperitoneal tissue and peritoneum. The musculature consists of a group 
of skeletal muscles which work in concert to provide the mechanical strength and flexibility 
necessary to move the torso, in addition to performing the primary function of the abdominal 
wall, counteracting the large pressure force exerted by the internal organs. Loss of this 
musculature is critical, as the muscles provide the majority of the abdominal wall’s mechanical 
strength. Skeletal muscle provides the bulk of the mechanical strength, mobility and flexibility 
of not only the abdominal wall but also the majority of the mobile components of the body. 
Skeletal muscle fibre development and regeneration are similar processes. In 
development, mononuclear myoblasts line up parallel to one another and fuse to produce 
multinucleated myotubes. The myotubes share the cytoplasm of the incorporated myoblasts 
and their nuclei are dispersed along its length. Once the myotubes are formed, they undergo a 
maturation process, during which they become innervated and vascularized, resulting in 
myofibres (Wilson et al., 1992). The parallel alignment of the myoblasts during fusion is key 
to the myofibres’ ability to produce the necessary force for movement and strength. Muscle 
regeneration and repair following trauma to the abdominal wall commences with the activation 
of satellite progenitor cells (Chen and Goldhamer, 2003; Dhawan and Rando, 2005; Wagers 
and Conboy, 2005). Once activated, these satellite cells migrate to the site of the defect and 
proliferate. Within the defect they create new myotubes by aligning parallel to the injured 
myofibres, and fuse to each other. These myotubes mature through innervation and 
vascularization to become functioning myofibres. Skeletal muscle tissue engineering depends 
on the regenerative properties of the satellite cells and their potential to proliferate and 
differentiate to form organized structures. Previous skeletal muscle tissue-engineering studies 
have focused on either the ability of muscle cells to contract engineered substrates or their 
potential to form myotubes whilst being cultured on those biomaterials (as films, hydrogels or 
nanofibres; Borschel et al., 2006; Kamelger et al., 2004; Saxena et al., 1999, 2001).  
In this study we report that the 3D PLLA–collagen scaffolds support enhanced 
myogenesis, especially those with an increasing ratio of oxidized collagen, with the 
differentiation of C2C12 cells to skeletal myoblasts and the formation of myotubes. In terms 
of cell differentiation, quantitative RT–PCR analysis of C2C12 myoblasts cultured on the 
scaffolds demonstrated expression of typical myogenic markers (MyoD, myogenin and 
MRF4). The scaffolds with higher-dose Oxicol sponge induced the greatest myogenesis, 
having the highest expression of the late myogenic markers myogenin and MRF4. Furthermore, 
the presence of MyHC in C2C12 cells cultured on this scaffold was clearly confirmed by 
subsequent immunofluorescent staining, demonstrating the development of multinucleated 
myosin-expressing myotubes. The design of the 3D composite sponges described in this study 
has allowed the possibility of the degradation rate to be tailored to the precise clinical 
application, having a combination of collagen modifications with differential degradation 
kinetics. Furthermore, we have demonstrated that sponges with higher-dose Oxicol facilitated 
myogenic differentiation and myotube formation.  
The myogenic response of the higher dose of oxidized collagen in the Oxicol scaffolds 
may be due to the change in surface topography that the specific ratio of GTA:oxidized 
collagen has caused. SEM observation of the high-dose oxidized collagen formulation clearly 
shows the presence of small-diameter fibres on the surface. Dang and Leong (2007) found that 
the topographical features of nanofibres having a diameter of several hundred nanometers was 
responsible for the myogenic induction of human mesenchymal stem cells (hMSCs) in in vitro 
culture. The precise mechanism of myogenic induction in C2C12 cells following culture on 
Oxicol scaffolds requires further investigation, as so far there has been no literature published 
which reports the effect of oxidation of collagen on induced myogenesis.  
Additionally, the 3D scaffolds were constructed so as to satisfy the criteria for bladder 
tissue engineering. Such scaffolds must be able to support the adhesion and proliferation of a 
number of cell types, including urothelial cells on the luminal side and smooth muscle cells 
surrounding the urothelial barrier. They must also be able to direct tissue maturation suitable 
for the formation of a functional bladder. It has been reported that many naturally derived and 
synthetic biomaterials, including collagen and PLLA, exhibit adequate in vitro 
biocompatibility for a large range of cell types, including bladder cells (Kim et al., 2000; 
Pariente et al., 2002). In this study, the 3D PLLA–collagen scaffolds facilitated effective 
seeding of primary smooth muscle cells derived from the porcine bladder. However, the cell 
population developed more satisfactorily in scaffolds that incorporated a collagen sponge than 
those without, improving the cell seeding and proliferation of bladder SMCs. The collagen 
sponge prepared with higher-dose Oxicol demonstrated better cell growth profiles than the 
lower-dose variants, suggesting that the higher dose favours cell adherence and proliferation. 
Previous research has demonstrated that vascular smooth muscle cells proliferate more actively 
when seeded on the surface of oxidized than unmodified collagen (Bacáková et al., 1997), 
although the mechanism of stimulation remains to be elucidated. It has been suggested that in 
SMC, oxidized low-density lipids stimulate mitogen-activated protein kinases (Chatterjee et 
al., 1997), and reactive oxygen species, such as superoxide anion, hydrogen peroxide and 
hydroxyl radicals increase autocrine production of mitogens, e.g. insulin-like growth factor 
(Bacáková et al., 1999). Similar effects could also be induced by Oxicol. Furthermore, the 
highest expression of the SMC functional marker αSMA was observed on this combined 
scaffold. As a result, the combination of PLLA mesh and collagen sponge with higher-dose 
Oxicol developed in this research is likely to be a valuable biomaterial for the regeneration of 
bladder tissue. 
For clinical applications, these scaffolds may be deployed in acellular form, without the 
additional seeding of cells or pre-seeded with autologous cells. The ability of the scaffolds to 
support enhanced cellular adhesion, proliferation and differentiation compared to conventional 
mesh biomaterials suggest that use of the device in a clinical setting will enhance tissue 
regeneration of skeletal and smooth muscle applications, such as abdominal wall defect and 
bladder repair. 
C2C12 is a permanent cell line derived from mouse skeletal muscle (Yaffe and Saxel, 
1977). These cells were used for this study because of their reliability, easy availability and 
ease of culture. Although C2C12 cells differentiate rapidly, form contractile myotubes and 
produce proteins characteristic of the muscle (Bains et al., 1984; Bennett and Tonks, 1997), 
C2C12 myooids possess less contractility than those from primary skeletal muscle cultures 
(Dennis and Kosnik, 2000; Dennis et al., 2001). However, previous studies using these cells 
suggest that the profile of maturation will be replicated in primary cultures. Future studies will 
focus on scaffold contractility and structure, using primary cells from primary mammalian 
skeletal muscle, and investigate the effect of mechanical conditioning on cell–scaffold 
constructs and to quantify their mechanical properties and active force capabilities. Additional 
clinical applications, such as congenital diaphragmatic hernia, may also be investigated. 
 
5. Conclusion 
In this study, we have demonstrated that the incorporation of higher-dose Oxicol within 
biodegradable PLLA–collagen scaffolds improves cell adhesion, proliferation and uniform 
distribution throughout the entire 3D collagen sponge for all of the cell types studied. The 3D 
scaffolds demonstrated enhanced myogenic differentiation and myotube formation through the 
expression of myogenic regulator genes and proteins, compared to simple 3D scaffolds 
constructed from PLLA and coated with unmodified collagen. The results suggest that these 
Oxicol scaffolds would enhance clinical reconstruction of abdominal wall defects. In addition, 
the greater αSMA protein expression, enhanced cell proliferation and sustained SMC 
phenotype promoted by this scaffold suggests that bSMCs grown on the scaffolds clinically 
are likely to have smooth muscle function. Together, our results indicate that these 3D 
biodegradable scaffolds constructed from PLLA textiles and high-dose Oxicol sponges can be 
used for the engineering of both smooth and skeletal muscle tissue, extending their role in 
regenerative medicine.  
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Table 1. Scaffolds used in the studies 
Table 2. Primers used for real time RT-PCR analysis 
Figure Captions  
1. SEM micrographs of PLLA-collagen scaffold. Scaffold A (a-c). (a) Knitted mesh with 
coated collagen, Mag = 50x; (b) Mag = 500x; (c) Cross-section of mesh, Mag = 150x; 
Scaffold B (d-f). (d) Mesh with the collagen sponge (80:20, GTA crosslinked : oxidised 
collagen,  Mag = 50x;  (e) Mag = 500x; (f) Cross-section of  the scaffold, Mag = 150x. 
Scaffold C, (g-i). (g) Mesh with the collagen sponge (50:50, GTA crosslinked : 
oxidised collagen,  Mag = 50x;  (e) Mag = 500x; (f) Cross-section of  the scaffold, Mag 
= 150x 
 
2. Characterization of porcine bladder smooth muscle (SM) cells (bSMCs). To confirm 
their SM cell phenotype, the cells were examined morphologically and by their protein 
expression. (a) bSMCs in culture - typical SM cell morphology; (b) inmmunostaining 
of α-SM actin on cultured bMSCs.  α-SM actin expressed in red and cell nuclei in blue; 
(c) confluent monolayer of bSMCs exhibited a characteristic ‘hill and valley’ 
morphology in the culture and expressed SM-MHC (in red) 
 
3. Viability and Proliferation of bSMCs on the scaffolds for up to 21 days. Confocal 
images of bSMCs cultured on scaffolds for 1 day (a-c) and 14 days (d-i); Cells stained 
green are live and red are dead.; SEM images of bSMCs grown on scaffolds for 21 days 
(g-l); Top side (g-i) and bottom side (j-l). (m) CyQUANT cell proliferation 
measurements of cell lysates from cell cultured on scaffolds. Cell-loaded scaffolds 
cultured after  1, 7 and 21 days, results represent mean and standard deviation, n = 4. p 
values show statistically significant differences among group (G) and day 1 (D). Error 
bars denote standard deviation, Scale bars represent 100 μm 
 
4. Confocal images of α-SM actin protein expressed on bSMCs cultured on scaffolds for 
up to 21 days, low (a-c) and high magnification (d-f). (a, d) Scaffold A; (b, e) Scaffold 
B; (c, f) Scaffold C; (g, h) Western blot analysis of  -SMA on scaffolds seeded with 
bSMCs. Cellular protein extracted from cell-loaded scaffolds were size separated by 
SDS-PAGE and transferred to a nitrocellulose membrane for detecting α-SM actin (g). 
Arbitrary optical densitometry (OD) units from western blot of α-SM actin expression. 
*p < 0.001 
 
5. Characterisation of C2C12 myoblast differentiation. Morphology of C2C12 myoblasts 
before and after differentiation, viewed using phase contrast microscopy. (a) 
Undifferentiated cells; (b) Differentiated C2C12 myoblasts demonstrating 
multinucleated, elongated myotubes; (c) Expression of myogenic differentiation factors 
on C2C12 myoblasts cultured in DM for 5 days and analysed by quantitative RT-PCR 
(n = 3) 
  
  
6. (a) Expression of Myogenic differentiation factors MyoD, Myogenin and MRF4 on 
C2C12 myoblasts cultured in DM on scaffolds for 1 and 7 days analysed by 
quantitative RT-PCR for (n = 3); (b) Expression of MyHC detected by 
immunofluorescence staining (red) on C2C12 myoblasts cultured on scaffolds in DM 
for 7 days 
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